KUS121, a VCP modulator, has an ameliorating effect on acute and chronic heart failure without calcium loading via maintenance of intracellular ATP levels.

[1]  L. Maier,et al.  SAR296968, a Novel Selective Na+/Ca2+ Exchanger Inhibitor, Improves Ca2+ Handling and Contractile Function in Human Atrial Cardiomyocytes , 2022, Biomedicines.

[2]  K. Campbell,et al.  Reduced cardiac muscle power with low ATP simulating heart failure , 2022, Biophysical journal.

[3]  Sabine Lotteau,et al.  Acute Genetic Ablation of Cardiac Sodium/Calcium Exchange in Adult Mice: Implications for Cardiomyocyte Calcium Regulation, Cardioprotection, and Arrhythmia , 2021, Journal of the American Heart Association.

[4]  Hiromu Ito,et al.  A VCP modulator, KUS121, as a promising therapeutic agent for post-traumatic osteoarthritis , 2020, Scientific Reports.

[5]  P. Ponikowski,et al.  Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. , 2020, The New England journal of medicine.

[6]  Ronald A. Li,et al.  Sarco/Endoplasmic Reticulum Ca2+-ATPase is a more effective calcium remover than Sodium-Calcium Exchanger in human embryonic stem cell-derived cardiomyocytes. , 2019, American journal of physiology. Heart and circulatory physiology.

[7]  Takeshi Kimura,et al.  Cardioprotective Effects of VCP Modulator KUS121 in Murine and Porcine Models of Myocardial Infarction , 2019, JACC. Basic to translational science.

[8]  R. Takahashi,et al.  KUS121, a valosin-containing protein modulator, attenuates ischemic stroke via preventing ATP depletion , 2019, Scientific Reports.

[9]  J. Reagan,et al.  Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction , 2019, JACC. Basic to translational science.

[10]  H. Bøtker,et al.  Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients , 2019, Circulation.

[11]  Kazuhiro Nakagawa,et al.  Unlabeled image analysis-based cell viability assay with intracellular movement monitoring. , 2019, BioTechniques.

[12]  P. Ponikowski,et al.  Treatments targeting inotropy. , 2018, European heart journal.

[13]  R. Takahashi,et al.  ATP Maintenance via Two Types of ATP Regulators Mitigates Pathological Phenotypes in Mouse Models of Parkinson's Disease , 2017, EBioMedicine.

[14]  R. Tian,et al.  Defective Branched-Chain Amino Acid Catabolism Disrupts Glucose Metabolism and Sensitizes the Heart to Ischemia-Reperfusion Injury. , 2017, Cell metabolism.

[15]  G. Pazour,et al.  Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness , 2017, Scientific Reports.

[16]  G. Filippatos,et al.  Mitochondrial function as a therapeutic target in heart failure , 2016, Nature Reviews Cardiology.

[17]  R. Foo,et al.  A Simplified, Langendorff-Free Method for Concomitant Isolation of Viable Cardiac Myocytes and Nonmyocytes From the Adult Mouse Heart. , 2016, Circulation research.

[18]  N. Yoshimura,et al.  Neuroprotective effects of VCP modulators in mouse models of glaucoma , 2016, Heliyon.

[19]  Y. Maejima,et al.  Drp1-Dependent Mitochondrial Autophagy Plays a Protective Role Against Pressure Overload–Induced Mitochondrial Dysfunction and Heart Failure , 2016, Circulation.

[20]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[21]  H. Meyer,et al.  The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis , 2014, Journal of Cell Science.

[22]  N. Yoshimura,et al.  Novel VCP modulators mitigate major pathologies of rd10, a mouse model of retinitis pigmentosa , 2014, Scientific Reports.

[23]  D. Kass,et al.  Nitroxyl (HNO): A Novel Approach for the Acute Treatment of Heart Failure , 2013, Circulation. Heart failure.

[24]  C. Clar,et al.  Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes , 2012, BMJ Open.

[25]  Jiaquan Xu,et al.  Deaths: final data for 2009. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[26]  D. Cox,et al.  Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure , 2011, Science.

[27]  A. Kakizuka,et al.  Enhanced ATPase activities as a primary defect of mutant valosin‐containing proteins that cause inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia , 2010, Genes to cells : devoted to molecular & cellular mechanisms.

[28]  Masafumi Kitakaze,et al.  ER stress in cardiovascular disease. , 2010, Journal of molecular and cellular cardiology.

[29]  K. Sipido,et al.  Pharmacological Inhibition of Na/Ca Exchange Results in Increased Cellular Ca2 Load Attributable to the Predominance of Forward Mode Block , 2008, Circulation research.

[30]  Stefan Neubauer,et al.  The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.

[31]  E. Wanker,et al.  Pathological consequences of VCP mutations on human striated muscle. , 2007, Brain : a journal of neurology.

[32]  M. Diaz,et al.  Enhanced sarcolemmal Ca2+ efflux reduces sarcoplasmic reticulum Ca2+ content and systolic Ca2+ in cardiac hypertrophy. , 2004, Cardiovascular research.

[33]  A. Pestronk,et al.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein , 2004, Nature Genetics.

[34]  E. Kranias,et al.  Calcium: Phospholamban: a crucial regulator of cardiac contractility , 2003, Nature Reviews Molecular Cell Biology.

[35]  M. Hori,et al.  The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. , 2002, Journal of the American College of Cardiology.

[36]  D. Burkhoff,et al.  PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor) Defective Regulation in Failing Hearts , 2000, Cell.

[37]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[38]  Bin Liu,et al.  Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. , 1996, Circulation research.

[39]  R A Bassani,et al.  Relaxation in rabbit and rat cardiac cells: species‐dependent differences in cellular mechanisms. , 1994, The Journal of physiology.

[40]  M. Stern,et al.  Theory of excitation-contraction coupling in cardiac muscle. , 1992, Biophysical journal.

[41]  C. Folmes,et al.  Myocardial fatty acid metabolism in health and disease. , 2010, Physiological reviews.

[42]  A. Parkhomenko,et al.  Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. , 2008, Critical care medicine.

[43]  I. Oye,et al.  Adenosine 3',5'-cyclic monophosphate in perfused rat hearts exposed to isoprenaline and dopamine. , 1976, Acta physiologica Scandinavica.